#United States #New York #Pomerantz LLP #Compass Therapeutics #CMPX

Pomerantz Law Firm Investigates Compass Therapeutics

Pomerantz LLP, a firm well-regarded for its class-action litigation expertise, has initiated an investigation on behalf of investors associated with Compass Therapeutics, Inc. This follow-up arises amid concerns of potential securities fraud and unethical business practices tied to recent developments in the company’s clinical studies.

On April 27, 2026, Compass Therapeutics released a press statement concerning the outcomes of a phase 2/3 clinical trial for its drug tovecimig, aimed at treating biliary tract cancer. The report highlighted that the study had successfully met one of its key secondary endpoints, specifically progression-free survival. However, it also disclosed a notable failure to meet another critical secondary endpoint, overall survival. This mixed outcome led to an immediate adverse reaction in the stock market, where share prices plummeted by $3.24, equivalent to a 64.41% decline, finishing the trading day at $1.79.

Investors may have a substantial interest in the results of this investigation, given the adverse market reaction that followed the announcement. Pomerantz’s inquiry aims to ascertain whether the company and its executives failed to disclose relevant information that led to inflated stock values prior to the trial results, a situation that could classify as securities fraud.

The firm has a historical commitment to defending the rights of investors impacted by corporate misconduct, with a legacy tracing back over 85 years. Abraham L. Pomerantz, the firm's founder, is often referred to as the dean of the class action bar for his pioneering work in this legal domain. Over the decades, Pomerantz LLP has successfully pursued numerous multimillion-dollar damage awards for their clients.

Investors looking for more information or wishing to join the class-action lawsuit can contact Danielle Peyton, an attorney at Pomerantz, at [email protected] or reach out via telephone at 646-581-9980 ext. 7980. Participation in the investigation could be crucial for those seeking to recover losses linked to their investment in Compass Therapeutics, particularly given the sharp decline in stock performance after the press release.

As the investigation unfolds, it may also bring to light broader implications for the transparency required of companies operating in the biopharmaceutical sector, especially regarding disclosures related to drug trial outcomes. Pomerantz is committed to ensuring accountability in corporate governance while advocating for investors' rights.

With a global presence that includes offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, Pomerantz stands as a key player in the corporate litigation landscape, continually fighting for justice against securities fraud, breaches of fiduciary responsibility, and other violations affecting investors.

Conclusion

The recent turbulence involving Compass Therapeutics underlines the vital importance of transparency in the biopharmaceutical industry. Investors should monitor this situation closely, as the Pomerantz investigation might reveal significant findings affecting their financial interests moving forward. For ongoing updates and further details regarding the lawsuit and its implications, consider following the developments closely within this evolving narrative.